Used to reduce excess abdominal fat in HIV patients, also stimulates growth hormone release.

Common Name:
Tesamorelin

Compound Name:
Tesamorelin Acetate, TH9507

Chemical Formula:
C221H366N72O67S

Molecular Weight:
5135.89 g/mol

Sequence and Amino Acid Composition:

• Sequence: Trans-3-Hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
• Amino Acid Profile:
  • Tyrosine (Y):
    • Frequency: 2
    • Properties: Aromatic, hydrophobic, precursor to neurotransmitters
    • Role in the Peptide: Increases the stability and receptor interaction of the peptide
  • Leucine (L):
    • Frequency: 4
    • Properties: Branched-chain amino acid, important for protein synthesis
    • Role in the Peptide: Essential for maintaining structural stability and enhancing receptor binding
  • Arginine (R):
    • Frequency: 3
    • Properties: Positively charged, involved in protein interactions
    • Role in the Peptide: Key for signal transduction and solubility
  • Others: Each amino acid is detailed similarly, indicating their frequency, chemical properties, and role in the peptide.

Structure:
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that is modified by the addition of a trans-3-hexenoyl group at the N-terminus, enhancing its stability and binding affinity.

Synthesis Method:
Synthesized through solid-phase peptide synthesis, which ensures high purity and allows for specific modifications that enhance its biological activity and stability.

Solubility:
Highly soluble in water and suitable for subcutaneous administration.

Stability:
Stable under refrigeration (2-8°C) for extended periods when kept in lyophilized form. After reconstitution, it should be used within a specified timeframe to maintain efficacy.

Function:
Tesamorelin significantly enhances the release of growth hormone from the pituitary gland, leading to an increase in plasma growth hormone levels.

Benefits and Uses:

• Primarily used for reducing belly fat in HIV-infected patients with lipodystrophy, a condition associated with the redistribution of body fat.
• Investigated for potential use in adults with growth hormone deficiency.
• May improve metabolic parameters and reduce cardiovascular risk factors associated with excess abdominal fat.

Side Effects:
Common side effects include injection site reactions (redness, itching, pain), headache, muscle pain, and symptoms resembling the flu. There may also be an increase in blood sugar levels.

Regulatory Status:
FDA-approved specifically for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.

ARTICLES

EXERCISES

COMMUNITY